RxDoctor Payments Data

Margaret Cusack

Family · Coppell, TXNPI 1902929987

Payments from drug & device makers

$5,433in general payments, 2019–2025

Across 224 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • AbbVie$611
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
  • Teva Pharmaceuticals USA, Inc.$232
  • Takeda Pharmaceuticals U.S.A., Inc.$218
  • Bausch Health US, LLC$200
  • plus $2K from 39 others

What the payments were for

  • Consulting fees$80015%
  • Travel & lodging$3286%
  • Food & beverage$4,30579%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,433 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$10,882
Medicare patients
48
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$14,465
MounjaroTirzepatide11$13,693
ValacyclovirValacyclovir Hcl20$521
Omeprazole15$514
Rosuvastatin Calcium39$333
Bupropion XlBupropion Hcl11$303
Levothyroxine Sodium17$278
Atorvastatin Calcium24$268
Losartan Potassium32$245
Metoprolol Succinate26$224
Chlorthalidone12$221
Paroxetine Hcl11$181
Lisinopril34$161
Trazodone Hcl17$154
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$14,46515 claims
Lilly USA, LLCMounjaro$128$13,69311 claims
Almatica Pharma LLCSertraline Hcl$37$9611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Coppell

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →